B
Braidwell Portfolio holdings
AUM
$2.7B
Turnover
43.12%
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
+2.32%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.92B
AUM Growth
+$79.1M
(+2.8%)
Cap. Flow
-$672M
Cap. Flow
% of AUM
-22.98%
Top 10 Holdings %
Top 10 Hldgs %
45.84%
Holding
68
New
6
Increased
13
Reduced
17
Closed
13
Avg Time Held
1.3
years
Top 10 Avg Time Held
0.8
years
Top 20 Avg Time Held
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Caris Life Sciences
CAI
|
+$197M |
| 2 |
Krystal Biotech
KRYS
|
+$48M |
| 3 |
Edgewise Therapeutics
EWTX
|
+$39.7M |
| 4 |
Inspire Medical Systems
INSP
|
+$31.9M |
| 5 |
Xenon Pharmaceuticals
XENE
|
+$29.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Transmedics
TMDX
|
+$65.9M |
| 2 |
Blueprint Medicines
BPMC
|
+$38.9M |
| 3 |
iRhythm Holdings
IRTC
|
+$33.1M |
| 4 |
Bicara Therapeutics
BCAX
|
+$28.2M |
| 5 |
Kiniksa Pharmaceuticals
KNSA
|
+$21.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.51% |
| 2 | Miscellaneous | 28.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
Kiniksa Pharmaceuticals
KNSA
$6.17B
| $30.5M | 1.04% |
1,102,580
-860,329
| -44% | -$21.9M |
2024 Q1
5 quarters
|
|
27
Harrow
HROW
$1.03B
| $26.6M | 0.91% |
872,246
-84,593
| -9% | -$2.27M |
2023 Q1
9 quarters
|
|
28
OrthoPediatrics
KIDS
$574M
| $23.8M | 0.81% |
1,107,770
| – | – |
2022 Q4
10 quarters
|
|
29
Maravai LifeSciences
MRVI
$973M
| $20.1M | 0.69% |
8,353,287
| – | – |
2023 Q2
8 quarters
|
|
30
DELISTED
Apellis Pharmaceuticals
APLS
| $19.4M | 0.66% |
1,121,034
-531,300
| -32% | -$9.83M |
2024 Q2
4 quarters
|
|
31
Sionna Therapeutics
SION
$184M
| $18.8M | 0.64% |
+1,081,855
| New | +$14.2M |
2025 Q2
0 quarters
|
|
32
Madrigal Pharmaceuticals
MDGL
$10.6B
| $18.4M | 0.63% |
60,781
+12,091
| +25% | +$3.6M |
2025 Q1
1 quarter
|
|
33
Repligen
RGEN
$11.4B
| $18M | 0.61% |
144,556
+62,900
| +77% | +$8M |
2023 Q2
8 quarters
|
|
34
Oruka Therapeutics
ORKA
$5.08B
| $17.1M | 0.58% |
1,524,842
-47,584
| -3% | -$496K |
2024 Q3
3 quarters
|
|
35
Castle Biosciences
CSTL
$1.01B
| $16.8M | 0.57% |
822,735
+457,488
| +125% | +$8.47M |
2025 Q1
1 quarter
|
|
36
UnitedHealth
UNH
$350B
| $15.4M | 0.53% |
+49,400
| New | +$18.9M |
2025 Q2
0 quarters
|
|
37
Globus Medical
GMED
$10.2B
| $14.6M | 0.5% |
+247,200
| New | +$16M |
2025 Q2
0 quarters
|
|
38
DELISTED
Day One Biopharmaceuticals
DAWN
| $14.2M | 0.49% |
2,181,598
-1,355,255
| -38% | -$9.32M |
2022 Q4
10 quarters
|
|
39
Xencor
XNCR
$1.77B
| $13M | 0.45% |
1,655,690
| – | – |
2024 Q3
3 quarters
|
|
40
Celcuity
CELC
$2.94B
| $11.8M | 0.4% |
884,306
| – | – |
2024 Q2
4 quarters
|
|
41
Crescent Biopharma
CBIO
$473M
| $4.22M | 0.14% |
+261,504
| New | +$5.53M |
2025 Q2
0 quarters
|
|
42
Replimune Group
REPL
$1.12B
| $3.93M | 0.13% |
422,887
-1,038,939
| -71% | -$9.07M |
2024 Q2
4 quarters
|
|
43
Zura Bio
ZURA
$430M
| $2.6M | 0.09% |
2,472,806
| – | – |
2024 Q3
3 quarters
|
|
44
Pulmonx
LUNG
$76.4M
| $1.95M | 0.07% |
752,541
| – | – |
2022 Q4
10 quarters
|
|
45
Surrozen
SRZN
$279M
| $1.25M | 0.04% |
+140,000
| New | +$1.28M |
2025 Q2
0 quarters
|
|
46
Ascendis Pharma A/S
ASND
$14.8B
| – | – |
-106,713
| Closed | -$16.6M | – |
|
47
Jade Biosciences
JBIO
$848M
| – | – |
-41,157
| Closed | -$3.62M | – |
|
|
48
DELISTED
Blueprint Medicines
BPMC
| – | – |
-439,968
| Closed | -$38.9M | – |
|
49
Cullinan Oncology
CGEM
$877M
| – | – |
-980,773
| Closed | -$7.42M | – |
|
50
Dianthus Therapeutics
DNTH
$4.23B
| – | – |
-375,355
| Closed | -$6.81M | – |
|
Similar funds
M
AG
NIM
GC
CCM
ACP
GBCP
SCM
Braidwell's Q2 2025 Portfolio in Review
As of Q2 2025, Braidwell held 68 positions worth $2.92B, up 2.8% from $2.84B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Braidwell withdrew a net $672M in Q2 2025, closing 13 positions and reducing 17 holdings. Its most notable exit was Blueprint Medicines, an estimated $38.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 67% a quarter earlier, followed by Miscellaneous.
Against the trend, Braidwell opened a new position in Caris Life Sciences worth $195M.
- Braidwell's largest Q2 2025 buy was Caris Life Sciences: 7,316,142 shares worth $195M.
- Braidwell added most to Krystal Biotech in Q2 2025, an estimated $48M increase.
- Braidwell's biggest Q2 2025 reduction was Transmedics, cutting an estimated $65.9M.
- Braidwell fully exited Blueprint Medicines in Q2 2025, selling an estimated $38.9M.
- Braidwell's ten largest holdings make up 46% of its $2.92B portfolio in Q2 2025.
- Braidwell opened 6 new positions and closed 13 in Q2 2025.
- Braidwell's portfolio value rose 2.8% quarter-over-quarter to $2.92B.
Based on Braidwell's 13F filing for Q2 2025, filed 14 Aug 2025.